Get started

Localsupport

Daily review of BTC interval 4HHello everyone, let's look at the BTC to USDT chart on the four hour timeframe. As you can see, the price is moving below the local downtrend line. Let's start with the support line and as you can see the first support on which the price is currently based is $16663 equal to 0.78 Fib, if the support is broken then the next support is $16419 and $15742. Now let's move to the resistance line, as you can see the first resistance is $16881, if you manage to break it, the next resistance will be $17107, $17281 and $17462. Looking at the CHOP indicator, we see that in the four-hour interval, the energy starts to bounce back from the bottom very slowly, the MACD confirms the downtrend, while the RSI is also at the bottom. The indicators presented may indicate a respite.
by cryptodailyuk
1
USDJPY Bearish flag almost complete, then it will move up!Welcome back! Let me know your thoughts in the comments! **USDJPY - Listen to video! We recommend that you keep this pair on your watchlist and enter when the entry criteria of your strategy is met. Please support this idea with a LIKE and COMMENT if you find it useful and Click "Follow" on our profile if you'd like these trade ideas delivered straight to your email in the future. Thanks for your continued support! Brian & Kenya Horton, BK Forex Academy
Long
by BKTradingAcademy
1
$AGLE Next Target PTs 1-1.50 and higherAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
ALong
by BADQOMOCAWGOWLD
$ENSVEnservco Corporation, through its subsidiaries, provides well enhancement and fluid management services to the onshore oil and natural gas industry in the United States. It offers frac water heating, hot oiling, pressure testing, acidizing, bacteria and scale treatment, freshwater and saltwater hauling, fluid disposal, frac tank rental, well site construction, and other general oil field services. The company owns and operates a fleet of approximately 338 specialized trucks, trailers, frac tanks, and other well-site related equipment. It operates in the eastern United States region comprising the southern region of the Marcellus Shale formation and the Utica Shale formation in eastern Ohio; Rocky Mountain region consisting of western Colorado and southern Wyoming, central Wyoming, western North Dakota, and eastern Montana; and the Central United States region, including Eagle Ford Shale and Permian Basin in Texas. Enservco Corporation was incorporated in 1980 and is headquartered in Longmont, Colorado.
ELong
by BADQOMOCAWGOWLD
$BFRI Next Target PT 10 and higherBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
NASDAQ:BFRILong
by BADQOMOCAWGOWLD
$IMRNImmuron stock rockets after funding by U.S. DoD of new research agreement Shares of Immuron Ltd. IMRN, +46.18% rocketed 49.6% in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD$6.2 million ($4.5 million) from the U.S. Department of Defense to evaluate Travelan for military use. Trading volume spiked to 1.3 million shares, compared with the full-day average of about 60,500. The award is aimed at testing the efficacy of a single larger dose regimen of Travelan for the treatment of moderate to severe diarrhea upon challenge with enterotoxigenic Escherichia coli (ETEC). "This new project expands our clinical development program and represents the first of several significant clinical trials which the Company expects to undertake with the US Military in 2022," said Immuron Chief Executive JErry Kanellos. "The new funding is testament to the value proposition our hyperimmune bovine polyclonal colostrum technology offers to benefit the US Military as well as the civilian international travelling population." The stock has tumbled 30.1% over the past three months while the iShares Biotechnology ETF IBB, -1.11% has declined 7.2% and the S&P 500 SPX, +0.28% has gained 8.3%.
NASDAQ:IMRNLong
by BADQOMOCAWGOWLD
1
BTCUSDT Strong local supports here can make price strong The market is getting bearish once again and if these local supports here break we can expect dump here to 40K support that is the last daily support left and, if and only if 40K support break market is dead for a while. But as we can see price is near strong local support and technically price can start a new local pump here or at least more range here is expected. Main support zones are now: A. 47K$ that price is near this support now B. 44K$support that is retest broken trendlines (blue zone on the chart) DISCLAIMER: ((trade based on your own decision )) <>
Long
by MMBTtrader
28
$AVCT SUPPORT AND RESISTANCE$AVCT: SI 14% | BC 150% SUPPORT AND RESISTANCE BULLISH CYPHER American Virtual Cloud Technologies, Inc. provides IT solutions and managed services. It offers managed IT services to a range of clients, including unified communications-as-a-service, directory and messaging, enterprise networking, cybersecurity, collaboration, data center, integration, storage, backup, virtualization, and converged infrastructure. The company was founded in 1987 and is based in Atlanta, Georgia.
ALong
by BADQOMOCAWGOWLD
2
$BTCUSDT If it pivots off local support, we have confirmation onWe can expect 3rd leg higher and more rise for the price here as indicated by neon green potential gains price range arrows on the chart and $BTC can easily hit Target PTs of 73,000-85,000 and higher on the next step. New local support formed based on Fiboancci and also broken trendline on the overall larger scale parallel uptrending lines. If it pivots off local support, we have confirmation on the uprise to the next 3rd step higher Cryptos tends to have Hype cycle in the Spring season...
BINANCE:BTCUSDLong
by BADQOMOCAWGOWLD
4
$SONX Parallel channelB of A Securities Initiates Coverage On Sonendo with Buy Rating, Announces Price Target of $15 Sonendo, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada. It provides GentleWave, a tooth decay treatment device for cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of ethylenediaminetetraacetic acid that is used to help debride and disinfect the root canal system. In addition, it provides The Digital Office, a practice management software that integrates digital office for dental practitioners. The company was formerly known as Dentatek Corporation and changed its name to Sonendo, Inc. in March 2011. Sonendo, Inc. was incorporated in 2006 and is headquartered in Laguna Hills, California.
SLong
by BADQOMOCAWGOWLD
$VYNE Support and ResistanceHC Wainwright & Co. Assumes VYNE Therapeutics at Buy, Announces Price Target of $7 VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
NASDAQ:VYNELong
by BADQOMOCAWGOWLD